Silicon Valley Bank in the spotlight (part II)

Plus analysis of Monday's latest biotech M&A news (Seagen & Provention Bio)

Following up on our SVB story last week, the wild weekend was followed by an eventful (or rather, thankfully uneventful) Monday, especially for the biotech world. The SVB fiasco saw a solution that was a relief for bio companies that held deposits there. Additionally, Monday morning was full of big buyouts. The Seagen & Pfizer rumors that were swirling …